GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nanda, Sitansu S. | - |
dc.contributor.author | Hossain, Md Imran | - |
dc.contributor.author | Ju, Heongkyu | - |
dc.contributor.author | Yi, Dong Kee | - |
dc.date.accessioned | 2021-09-20T06:40:47Z | - |
dc.date.available | 2021-09-20T06:40:47Z | - |
dc.date.created | 2021-09-20 | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 1389-4501 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82187 | - |
dc.description.abstract | Background: Glycogen syntheis kinase (GSK-3) inhibitors are novel therapeutic agents for treating various types of cancer, such as breast, lung, and gastric cancer. No pathological changes have been found by the morphological examination of GSK-3. Objectives: This review describes recent procedures using GSK-3 inhibitors, primarily in treating colon carcinoma. Furthermore, it also explains the mechanism of action of different GSK-3 inhibitors in treating various types of cancers and proposes some additional mechanisms may be useful for further research on GSK-3 inhibitors for cancers, including colon carcinoma. Results: The majority of the cancerous and pre-cancerous lesions are stimulated by the transformation of membrane-bound arachidonic acid (AA) to eicosanoids, a transformation that promotes for the viability, proliferation, and spread of cancer. GSK-3 inhibitors can reinstate hostility to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) responsiveness in gastric adenocarcinoma cells. GSK-3, the final enzyme in glycogen synthesis, is a serine/threonine kinase that phosphorylates varied sequences that are more than a hundred in number, within proteins in an array of heterogeneous pathways. It is an essential module of an exceptionally large number of cellular processes, playing a fundamental role in many metabolic processes and diseases. Many patients diagnosed with colon cancer achieve long-term remission with outstanding survival through the GSK-3 inhibitors. Conclusion: Prior to the extensive application of these proposed mechanisms of GSK-3 inhibitor, further evaluation and clinical studies are needed. Only after the completion of appropriate clinical studies and morphological examinations, would extensive application be apprpriate. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BENTHAM SCIENCE PUBL LTD | - |
dc.relation.isPartOf | CURRENT DRUG TARGETS | - |
dc.title | GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000692681000003 | - |
dc.identifier.doi | 10.2174/1389450122666210204203950 | - |
dc.identifier.bibliographicCitation | CURRENT DRUG TARGETS, v.22, no.13, pp.1485 - 1495 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85116474531 | - |
dc.citation.endPage | 1495 | - |
dc.citation.startPage | 1485 | - |
dc.citation.title | CURRENT DRUG TARGETS | - |
dc.citation.volume | 22 | - |
dc.citation.number | 13 | - |
dc.contributor.affiliatedAuthor | Ju, Heongkyu | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | GSK-3 inhibitor | - |
dc.subject.keywordAuthor | Colon Carcinoma | - |
dc.subject.keywordAuthor | Colorectal Cancer | - |
dc.subject.keywordAuthor | OMM | - |
dc.subject.keywordAuthor | Cancer Cell Apoptosis | - |
dc.subject.keywordAuthor | DMSO | - |
dc.subject.keywordPlus | GLYCOGEN-SYNTHASE KINASE-3 | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | DIALLYL DISULFIDE | - |
dc.subject.keywordPlus | BETA-CATENIN | - |
dc.subject.keywordPlus | CELL-SURVIVAL | - |
dc.subject.keywordPlus | INDUCED APOPTOSIS | - |
dc.subject.keywordPlus | WNT/BETA-CATENIN | - |
dc.subject.keywordPlus | DRUG-RESISTANCE | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.